Compass Financial Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Compass Financial Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$588K	Buy	+600,230	New	+$693K	0.07%	251

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GWP

Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return

Compass Financial Management's ATNM Position: Q2 2026 in Review

Compass Financial Management opened a new position in Actinium Pharmaceuticals (ATNM) in Q2 2026: 600,230 shares worth $588K. The stake represents 0.07% of the portfolio and ranks #251 among its holdings.

46 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

Compass Financial Management held 600,230 shares of Actinium Pharmaceuticals worth $588K as of Q2 2026.
Actinium Pharmaceuticals was a new Compass Financial Management position in Q2 2026.
Actinium Pharmaceuticals made up 0.07% of Compass Financial Management's portfolio in Q2 2026, its #251 holding.
46 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.